Bezafibrate

DB01393

small molecule approved investigational

Deskripsi

Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

Struktur Molekul 2D

Berat 361.819
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1-2 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Bezafibrate is almost completely absorbed after oral administration. The relative bioavailability of bezafibrate retard compared to the standard form is about 70%.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Take with a full glass of water.
  • 2. Take with food. Taking bezafibrate with food or after meals slows the absorption of bezafibrate.

Interaksi Obat

425 Data
Pravastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin.
Lovastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Lovastatin.
Cerivastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Cerivastatin.
Simvastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Simvastatin.
Atorvastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Atorvastatin.
Fluvastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Fluvastatin.
Rosuvastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Rosuvastatin.
Mevastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Mevastatin.
Pitavastatin Bezafibrate may increase the myopathic rhabdomyolysis activities of Pitavastatin.
Linezolid Linezolid may increase the hepatotoxic activities of Bezafibrate.
Furazolidone Furazolidone may increase the hepatotoxic activities of Bezafibrate.
Procaine Procaine may increase the hepatotoxic activities of Bezafibrate.
Tranylcypromine Tranylcypromine may increase the hepatotoxic activities of Bezafibrate.
Phenelzine Phenelzine may increase the hepatotoxic activities of Bezafibrate.
Minaprine Minaprine may increase the hepatotoxic activities of Bezafibrate.
Selegiline Selegiline may increase the hepatotoxic activities of Bezafibrate.
Procarbazine Procarbazine may increase the hepatotoxic activities of Bezafibrate.
Moclobemide Moclobemide may increase the hepatotoxic activities of Bezafibrate.
Isocarboxazid Isocarboxazid may increase the hepatotoxic activities of Bezafibrate.
Rasagiline Rasagiline may increase the hepatotoxic activities of Bezafibrate.
Pargyline Pargyline may increase the hepatotoxic activities of Bezafibrate.
Clorgiline Clorgiline may increase the hepatotoxic activities of Bezafibrate.
Iproniazid Iproniazid may increase the hepatotoxic activities of Bezafibrate.
Nialamide Nialamide may increase the hepatotoxic activities of Bezafibrate.
Safinamide Safinamide may increase the hepatotoxic activities of Bezafibrate.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hepatotoxic activities of Bezafibrate.
Methylene blue Methylene blue may increase the hepatotoxic activities of Bezafibrate.
Hydracarbazine Hydracarbazine may increase the hepatotoxic activities of Bezafibrate.
Pirlindole Pirlindole may increase the hepatotoxic activities of Bezafibrate.
Toloxatone Toloxatone may increase the hepatotoxic activities of Bezafibrate.
Benmoxin Benmoxin may increase the hepatotoxic activities of Bezafibrate.
Mebanazine Mebanazine may increase the hepatotoxic activities of Bezafibrate.
Octamoxin Octamoxin may increase the hepatotoxic activities of Bezafibrate.
Pheniprazine Pheniprazine may increase the hepatotoxic activities of Bezafibrate.
Phenoxypropazine Phenoxypropazine may increase the hepatotoxic activities of Bezafibrate.
Pivhydrazine Pivhydrazine may increase the hepatotoxic activities of Bezafibrate.
Safrazine Safrazine may increase the hepatotoxic activities of Bezafibrate.
Caroxazone Caroxazone may increase the hepatotoxic activities of Bezafibrate.
Harmaline Harmaline may increase the hepatotoxic activities of Bezafibrate.
Brofaromine Brofaromine may increase the hepatotoxic activities of Bezafibrate.
Ezetimibe The risk or severity of adverse effects can be increased when Bezafibrate is combined with Ezetimibe.
Clofibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Bezafibrate.
Fenofibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Bezafibrate.
Gemfibrozil The risk or severity of adverse effects can be increased when Gemfibrozil is combined with Bezafibrate.
Etofibrate The risk or severity of adverse effects can be increased when Bezafibrate is combined with Etofibrate.
Ciprofibrate The risk or severity of adverse effects can be increased when Bezafibrate is combined with Ciprofibrate.
Simfibrate The risk or severity of adverse effects can be increased when Bezafibrate is combined with Simfibrate.
Ronifibrate The risk or severity of adverse effects can be increased when Bezafibrate is combined with Ronifibrate.
Aluminium clofibrate The risk or severity of adverse effects can be increased when Bezafibrate is combined with Aluminium clofibrate.
Clofibride The risk or severity of adverse effects can be increased when Bezafibrate is combined with Clofibride.
Fenofibric acid The risk or severity of adverse effects can be increased when Bezafibrate is combined with Fenofibric acid.
Glycochenodeoxycholic Acid The therapeutic efficacy of Glycochenodeoxycholic Acid can be decreased when used in combination with Bezafibrate.
Cholic Acid The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Bezafibrate.
Glycocholic acid The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Bezafibrate.
Deoxycholic acid The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Bezafibrate.
Taurocholic acid The therapeutic efficacy of Taurocholic acid can be decreased when used in combination with Bezafibrate.
Obeticholic acid The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Bezafibrate.
Chenodeoxycholic acid The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Bezafibrate.
Taurochenodeoxycholic acid The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Bezafibrate.
Tauroursodeoxycholic acid The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Bezafibrate.
Bamet-UD2 The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Bezafibrate.
Dehydrocholic acid The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Bezafibrate.
Hyodeoxycholic Acid The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Bezafibrate.
Ursodeoxycholic acid The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Bezafibrate.
Sulpiride The risk or severity of adverse effects can be increased when Bezafibrate is combined with Sulpiride.
Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Bezafibrate.
Cyclosporine The risk or severity of renal failure can be increased when Cyclosporine is combined with Bezafibrate.
Glimepiride The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Glimepiride.
Acetohexamide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Acetohexamide.
Chlorpropamide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Chlorpropamide.
Tolazamide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Tolazamide.
Glyburide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Glyburide.
Glipizide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Glipizide.
Gliclazide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Gliclazide.
Tolbutamide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Tolbutamide.
Gliquidone The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Gliquidone.
Glisoxepide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Glisoxepide.
Glibornuride The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Glibornuride.
Carbutamide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Carbutamide.
Metahexamide The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Metahexamide.
Colestipol Colestipol can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colesevelam Colesevelam can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholestyramine Cholestyramine can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dicoumarol The risk or severity of bleeding can be increased when Bezafibrate is combined with Dicoumarol.
Phenindione The risk or severity of bleeding can be increased when Bezafibrate is combined with Phenindione.
Coumarin The risk or severity of bleeding can be increased when Bezafibrate is combined with Coumarin.
(R)-warfarin The risk or severity of bleeding can be increased when Bezafibrate is combined with (R)-warfarin.
Tioclomarol The risk or severity of bleeding can be increased when Bezafibrate is combined with Tioclomarol.
(S)-Warfarin The risk or severity of bleeding can be increased when Bezafibrate is combined with (S)-Warfarin.
Acenocoumarol The risk or severity of bleeding can be increased when Bezafibrate is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Bezafibrate is combined with 4-hydroxycoumarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Bezafibrate is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of bleeding can be increased when Bezafibrate is combined with Fluindione.
Clorindione The risk or severity of bleeding can be increased when Bezafibrate is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Bezafibrate is combined with Diphenadione.
Warfarin The risk or severity of bleeding can be increased when Bezafibrate is combined with Warfarin.
Tacrolimus Tacrolimus may increase the nephrotoxic activities of Bezafibrate.
Pitolisant The serum concentration of Bezafibrate can be decreased when it is combined with Pitolisant.
Valsartan The excretion of Valsartan can be decreased when combined with Bezafibrate.

Target Protein

Peroxisome proliferator-activated receptor delta PPARD
Peroxisome proliferator-activated receptor gamma PPARG
Peroxisome proliferator-activated receptor alpha PPARA
Nuclear receptor subfamily 1 group I member 2 NR1I2
Retinoic acid receptor RXR-alpha RXRA
Retinoic acid receptor RXR-beta RXRB
Retinoic acid receptor RXR-gamma RXRG

Referensi & Sumber

Artikel (PubMed)
  • PMID: 10880410
    Authors unspecified: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000 Jul 4;102(1):21-7.
  • PMID: 15911729
    Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005 May 23;165(10):1154-60.
  • PMID: 15123532
    Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 3.
  • PMID: 16606809
    Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006 Apr 10;166(7):737-41.

Contoh Produk & Brand

Produk: 5 • International brands: 6
Produk
  • Act-bezafibrate SR
    Tablet, extended release • 400 mg • Oral • Canada • Approved
  • Bezalip SR
    Tablet, extended release • 400 mg • Oral • Canada • Approved
  • Bezalip Tab 200mg
    Tablet • 200 mg • Oral • Canada • Approved
  • Jamp-bezafibrate SR
    Tablet, extended release • 400 mg • Oral • Canada • Generic • Approved
  • PMS-bezafibrate
    Tablet • 200 mg • Oral • Canada • Generic • Approved
International Brands
  • Befizal
  • Bezalip
  • Bezalip retard
  • Bezatol
  • Bezatol SR
  • Cedur

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul